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Abstract
Background: This is a randomized, controlled trial of preoperative chemotherapy in patients undergoing surgery
for oesophageal squamous cell carcinoma (OSCC). Patients were allocated to chemotherapy, consisting of 2-4
cycles of cisplatin and etoposide, followed by surgery (CS group) or surgery alone (S group). Initial results reported
only in abstract form in 1997, demonstrated an advantage for overall survival in the CS group. The results of this
trial have been updated and discussed in the timeframe in which this study was performed.
Methods: This trial recruited 169 patients with OSCC, 85 patients assigned to preoperative chemotherapy and 84
patients underwent immediate surgery. The primary study endpoint was overall survival (OS), secondary endpoints
were disease free survival (DFS) and pattern of failure. Survival has been determined from Kaplan-Meier curves and
treatment comparisons made with the log-rank test.
Results: There were 148 deaths, 71 in the CS and 77 in the S group. Median OS time was 16 months in the CS
group compared with 12 months in the S group; 2-year survival rates were 42% and 30%; and 5-year survival rates
were 26% and 17%, respectively. Intention to treat analysis showed a significant overall survival benefit for patients
in the CS group (P = 0.03, by the log-rank test; hazard ratio [HR] 0.71; 95%CI 0.51-0.98). DFS (from landmark time of
6 months after date of randomisation) was also better in the CS-group than in the S group (P = 0.02, by the log-
rank test; HR 0.72; 95%CI 0.52-1.0). No difference in failure pattern was observed between both treatment arms.
Conclusions: Preoperative chemotherapy with a combination of etoposide and cisplatin significantly improved
overall survival in patients with OSCC.
Background
Oesophageal squamous cell carcinoma (OSCC) accounts
for most cases of oesophageal cancer worldwide [1,2].
Even after complete surgical dissection, the prognosis of
patients with OSCC is poor, with 5-year survival rates of
20 to 30%. Factors that contribute to this dismal prog-
nosis include presence of locally advanced disease and
undetected metastatic cancer at diagnosis. Because of
the high rates of locoregional and distant failure, there
is much interest in the combination of systemic che-
motherapy and local surgical treatment.
The potential benefits of preoperative chemotherapy
include increasing the likelihood of curative resection by
downstaging the tumour and rapidly improving tumour-
related symptoms. It is also been thought that systemic
chemotherapy could contribute to the eradication of
micro-metastases and circulating tumour cells. More
recently, the importance of systemic disease control has
been emphasized by new insights in the metastasizing
process of cancer [3]. For decades, the dissemination of
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cancer has been considered the final stage in a deterior-
ating process. Now, there is accumulating evidence that
dissemination already can occur at an early stage of the
disease [4]. In theory, the use of preoperative che-
motherapy may therefore have a positive impact on sur-
vival of patients with oesophageal cancer. Here, we
report the design and long-term results of a randomized
controlled trial in patients with resectable OSCC, com-
paring preoperative chemotherapy with cisplatin and
etoposide followed by surgery to surgery alone.
Methods
All eligible patients had histologically confirmed squa-
mous cell carcinoma of the intra-thoracic ooesophagus.
Patients were deemed resectable if the disease was clini-
cally limited to the locoregional area (tumour stage 1, 2
or 3; any nodal stage and no metastases). Patients with
carcinoma of the distal oesophagus and suspected celiac
lymph nodes involvement (M1a) were also considered
eligible for surgery. Patients had to be below 80 years of
age, in adequate physical condition (Karnofsky score
>70) to undergo surgery and had to have adequate
hepatic, renal and bone marrow function. Exclusion cri-
teria were synchronous cancer, tumour localization in
the cervical ooesophagus (upper border, <18 cm from
the incisor teeth), severe cardiovascular or pulmonary
disease. Patients with previous malignancies were eligi-
ble if more than 5 years had elapsed from diagnosis
without evidence of tumour recurrence; exceptions were
made for adequately treated basal cell cancer of the skin
or carcinoma in situ of the cervix. Preoperative work-up
included clinical examination, oesophago-gastroscopy
with biopsies, chest radiography, external ultrasonogra-
phy of the cervical and upper abdominal region and
computed tomography (CT) of the chest and abdomen.
Radionuclide bone scans were performed if indicated.
Bronchoscopy was performed when the primary tumour
was adjacent to the trachea or main stem bronchus and
invasion was suspected.
Central randomisation took place at the Erasmus Uni-
versity Medical Center in Rotterdam (by trial coordina-
tor TCK). Random assignment was stratified by age
(<50; 51-60; >60), gender (male; female), weight loss
(kg) in the past four months (0-5; 6-10; >10) and length
of the tumour (cm) as measured by oesophago-gastro-
scopy (1-3; 4-6; 7-10; >10). Patients assigned to preo-
perative chemotherapy were treated with two cycles,
followed by a clinical response evaluation. Response eva-
luation was done three to four weeks after the last cycle
of chemotherapy. Clinical response after chemotherapy
was evaluated by oesophago-gastroscopy and CT of the
chest and abdomen. Tumour responses were assessed
according to the World Health Organisation (WHO)
criteria [5]. Complete absence of any evidence of
malignant disease, including negative biopsies from the
former tumour area, was defined as complete response
(CR). Partial response (PR) was defined as >50% reduc-
tion of tumour bulk, without the appearance of new
lesions. Stable disease (SD) was defined as <50% reduc-
tion of tumour bulk, without the appearance of new
lesions. Progressive disease (PD) was defined as >25%
progression of tumour bulk or the appearance of new
lesions. Patients with complete or partial responses
received two additional courses of chemotherapy,
whereas non-responding patients (stable disease or pro-
gressive disease) were referred for immediate surgery.
Patients with progressive disease (T4 or M1 disease)
were treated palliative and observed for survival.
Patients, who were randomly assigned to undergo sur-
gery alone, underwent the operation as soon as possible.
Patients who received chemotherapy were operated 4 to
6 weeks after the last treatment cycle. The study proto-
col was approved by the ethics committee of all partici-
pating institutions and written informed consent was
obtained from all patients.
Chemotherapy
Cisplatin, at a dose of 80 mg/m2, was given intrave-
nously over 4 hours on day one of each cycle preceded
and followed by adequate hydration. Etoposide, at a
dose of 100 mg/m2, was administered intravenously over
2 hours on day 1 (before cisplatin) and day 2, followed
by etoposide 200 mg/m2 orally on days 3 and 5. This
course was repeated in week 4. In case of clinical
response, two subsequent courses of chemotherapy were
administered in week 8 and 11. All patients received
prophylactic anti-nausea treatment with 5-HT 3 recep-
tor antagonists during chemotherapy. Treatment related
toxicities were measured according to the WHO recom-
mendations [5]. Re-treatment with the next cycle was
permitted only if the absolute neutrophil count was at
least 3,500/mm3, and the platelet count was at least
100,000/mm3. A delay of treatment of up to 2 weeks
was permitted. In patients with severe toxic renal or
neurological effects (≥ WHO grade 3) chemotherapy
was stopped and patients were referred for surgery.
Surgery and pathological examination
For carcinomas of the upper half of the intra-thoracic
ooesophagus a right-sided thoracotomy was performed.
For carcinomas of the lower half of the intra-thoracic
ooesophagus a transhiatal oesophagectomy was done.
The tumour and its adjacent lymph nodes were dis-
sected en bloc. The left gastric artery was transected at
its origin, with resection of local lymph nodes. The con-
tinuity of the digestive tract was restored by means of
gastric tube reconstruction or colonic interposition with
a cervical anastomosis. The tumour stage after resection
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was classified according to the TNM classification of the
International Union Against Cancer [6]. Resections were
classified as radical when microscopical examination
revealed all margins to be free of tumour (R0). Resec-
tions were considered not radical, if microscopically
examination showed tumour-positive circumferential
margin (R1) or presence of macroscopic disease (R2).
Follow-up
All patients were followed at an interval of three to four
months during the first year, every six months for the
second year, and annually for up to 5 years post surgery.
After 5 years, follow-up data were obtained by telephone
from the patient or his/her family practitioner. Recur-
rence of disease was diagnosed on clinical grounds.
However, whenever a relapse was suspected, radiologic,
endoscopic, or histologic confirmation was sought for.
Loco-regional disease recurrence was defined as
relapse at the primary site including the anastomosis or
in regional lymph nodes. Distant disease recurrence was
defined as distant lymph node sites or involvement of
distant organs including lung, liver, bone, and subcuta-
neous tissue.
Statistical analysis
The planned number of patients to be entered in the
study was 80 for each treatment arm. With these num-
bers of patients the statistical power should be sufficient
(power = 0.8; significance 0.05) to detect an increase of
the median survival from 10 to 18 months.
Overall survival (OS) was calculated from the date of
random assignment to date of death from any cause and
surviving patients were censored at the date they were
last known to be alive. Disease-free survival (DFS) was
calculated from a landmark time of 6 months after date
of randomisation to allow for the difference in timing of
surgery between the two treatment groups [7]. In this
analysis, events including macroscopically incomplete
resection, local and distant recurrence, and death arising
within the first 6 months after random assignment were
regarded as events at this landmark time. Survival curves
are presented by the Kaplan-Meier method and treat-
ment comparisons are by the log-rank test.
Statistical analyses were performed using the SPSS sta-
tistical package (SPSS Inc., Chicago, IL, USA). Hazard
ratios (HR) were calculated with the use of a Cox
regression model including treatment alone (primary
analysis) and after adjustment for baseline stratification
factors. Categorical data were compared with the use of
chi-square test or Fisher’s exact test, with a test for
trend over ordered categories. All statistical comparisons
were made with two-tailed tests and P values < 0.05
were reported as significant.
Results
Between January, 1989, and January, 1996, 169 patients
from six Dutch University Hospitals (Rotterdam,
Amsterdam, Utrecht, Groningen, Nijmegen and Maas-
tricht) were randomly assigned to either chemotherapy
followed by surgery (CS group, N = 85) or surgery alone
(S group, N = 84; Figure 1). An additional number of
nine patients were included to adjust for study drop-
outs. The majority of patients (N = 122) were included
by the Erasmus Medical Center (EMC), Rotterdam.
From all participating centers, the EMC is the only hos-
pital that collected outcome data (prospectively) for all
patients with oesophageal cancer referred in time this
study was performed. Between January, 1989, and Janu-
ary, 1996, 257 patients with OSCC were referred to the
EMC. Of these, 183 patients were deemed eligible for
surgical resection, of which 122 (67%) were included in
this trial. The reasons why 61 (33%) patients were not
randomized for this trial are not well documented.
Table 1 shows that the two groups were similar in
terms of age, sex, and performance status. Distribution
according to weight loss and size of the tumour was
also balanced. One patient, allocated to preoperative
chemotherapy, had a tumour located in the cervical part
of the oesophagus (the reason why this patient was
included and randomized remains unclear, even after
retrospective analysis of the patient’s record). Preopera-
tive staging by CT of the chest and the upper abdomen
was performed in 149 patients (88%); two patients (1%)
died before the planned CT scan; six patients (4%) were
staged by endoscopic ultrasound, external ultrasonogra-
phy of the cervical and upper abdominal region and
chest radiography. From twelve patients (7%) no addi-
tional information on preoperative staging was available.
Chemotherapy
Of the 85 patients assigned to preoperative chemother-
apy, 80 (94%) received chemotherapy; 75 (88%) patients
had two or more cycles and 5 patients (13%) received
one cycle. The reasons why no chemotherapy or only
one cycle was given were patient’s refusal (N = 3), death
(N = 1), tumour bleeding (N = 3) and renal toxicity
grade III (N = 1). Two patients allocated to preoperative
chemotherapy, were directly lost to follow-up after ran-
domization. Tracing back the original patient’s files was
impossible; therefore, it is not clear if these two patients
truly received chemotherapy followed by surgery.
Clinical response evaluation after two cycles of che-
motherapy showed 43 patients with stable or progressive
disease. Partial response to chemotherapy was observed in
32 patients. Of these, 30 patients received two additional
cycles of chemotherapy; one received one additional cycle
and one had three additional cycles of chemotherapy.
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Clinical response evaluation after the additional cycles of
chemotherapy showed six patients with complete
response; 20 patients had partial response; five showed
stable disease and one had progressive disease.
Detailed data on chemotherapy related toxicity is not
available. In the prior phase II trial a high rate of grade III
and IV nausea (38%) and vomiting (20%) was observed,
probably due to the fact that 5-HT3 receptor blockers were
rarely given throughout the study period [8]. All patients in
the current trial received prophylactic anti-nausea treat-
ment with 5-HT 3 receptor antagonists during chemother-
apy. No grade III or IV nausea and vomiting were observed.
The major non-hematological toxicity (grade III) was alope-
cia. Hematological toxicity grade III was observed in 23
patients (one renal, twenty-two hematological). Eight
patients had grade IV hematological toxicity.
Outcome of surgery
Surgery was performed in 76 CS and 82 S patients
(Table 2). Median time from randomization to surgery
was 14 days in the S group. In the CS group, the med-
ian time from randomization to surgery was 63 days
(36-123) for patients who received two cycles of che-
motherapy, and 114 days (54-165) for patients who
received additional treatment cycles. Four patients (5%)
in the CS group and three patients (4%) in S group died
within 30-days after surgery.
Data on postoperative complications was available of
67/76 (88%) of patients in the CS group and 75/82
(91%) patient in the S group. The frequency of nonfatal
postoperative events was closely similar in both groups
(table 2). However, pulmonary complications were sig-
nificantly more observed in the CS group (P = 0.041).
Oesophagectomy was performed in 91% (69/76) in the
CS-group and 85% (70/82) in the S-group. In the CS
group, six patients did not receive an oesphagectomy
because of tumour growth in adjacent structures (aorta
or bronchial tree) and one had tumour positive celiac
lymph nodes at laparotomy. In the S group, seven
patients did not undergo surgical resection because of
Figure 1 CONSORT Flow-diagram: random assignment, and compliance to the allocated treatment. CTX, chemotherapy
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tumour encasement of the aorta or the bronchial tree
and five due to tumour positive celiac lymph nodes at
laparotomy. Of the 69 patients in the CS group who
underwent surgical resection, 71% had R0 resections,
25% had R1 resections, and 4% had R2 resections. Of
the 70 patients in the S group who underwent surgical
resection, 57% had R0 resections, 29% had R1 resec-
tions, and 14% had R2 resections. Although more
patients in the CS group had R0 resections as compared
with the S group, no significant differences was observed
(P = 0.09). However, there was a significant difference
between the number of R2 resections in both treatment
arm (P = 0.04). Also the number of patients with lymph
node involvement (N1 or M1a) did not differ between
both treatment arms (43 and 46% in the CS group and
S group, respectively). In the CS group, the pathological
complete response rate (pT0N0M0) was 7%.
Pattern of failure
The outcomes of treatments were considered according
to findings at operation and to patterns of disease pro-
gression (first disease-free survival event; Table 3). The
rates of unresectable tumors or macroscopically incom-
plete resections were higher in the S group (P = 0.23; P
= 0.05 respectively). The pattern of first disease progres-
sion was similar between both treatment groups; in par-
ticular there was no clear trend toward fewer patients
with distant metastases as first site of relapse in the CS
group. Ten patients treated with preoperative che-
motherapy developed a second primary tumor; seven
squamous cell carcinomas of head and neck, one pan-
creatic, one lung and one breast carcinoma. In contrast,
four patients who underwent immediate surgical resec-
tion developed a second primary tumour, all squamous
cell carcinomas of head and neck.
Overall and disease-free survival
At the time of analysis, the median follow-up was 15
months in the CS group and 14 months in the S group.
In an intention-to-treat survival analysis, two patients
that were directly lost to follow-up were censored one
month after the date of randomization. OS on intention
to treat basis is shown in Figure 2. The median overall
survival in the CS group was 16 months, and in the S
group 12 months. OS was better in the CS group than
in the S group (P = 0.03, by the log-rank test; HR 0.71;
95%CI 0.51-0.98; Figure 2A). Survival at one year was
64% for those allocated to chemotherapy, 52% for those
allocated to surgery alone; at two years 42% and 30%; 5-
years, survival was 26% and 17%, respectively.
DFS is shown in Figure 2B. For DFS, 59 patients in
the CS group and 40 patients in the S group remained
for analysis after the landmark period of six months. In
6/59 (10%) patients in the CS group the date of disease
recurrence was not documented. In these, the date of
disease recurrence was estimated four months earlier
than the date of death (in the CS group the median
time between date of recurrence and date of death was
four months). In the CS group, there is prolonged DFS
compared with the surgical resection alone group (P =
0.02, by the log-rank test; HR 0.72; 95%CI 0.52-1.0).
Overall survival according clinical response to preo-
perative chemotherapy showed that patients with clinical
partial or complete response (those who received three
or more cycles of therapy) had significantly better over-
all survival then those with stable or progressive disease
(P = <0.001, by log-rank test; HR 0.38; 95%CI 0.23-0.65).
Figure 3 shows no clear evidence that effect of che-
motherapy varied in accordance with age, sex or length of
Table 1 Patient’s characteristics
Total CS
group
S group
Characteristics (N = 169) (N = 85 ) (N = 84) P-value*
Age, years 0,73
<50 31 (18%) 17 (20%) 14 (17%)
51-60 54 (32%) 25 (29%) 29 (34%)
>60 84 (50%) 43 (51%) 41 (49%)
Median 60 60 60
Range 35 - 79 35 - 76 37 - 79
Sex 0,9
Male 126 (75%) 63 (74%) 63 (75%)
Female 43 (25%) 22 (26%) 21 (25%)
Weight loss (% of normal
weight)
0,24
<5 56 (33%) 30 (35%) 26 (31%)
6-10 40 (24%) 16 (19%) 24 (29%)
>10 51 (30%) 30 (35%) 21 (25%)
Not recorded 22 (13%) 9 (11%) 13 (15%)
Tumor length (cm) 0,17
<3 27 (16%) 14 (17%) 13 (16%)
4-6 69 (41%) 36 (42%) 33 (39%)
7-10 55 (32%) 22 (26%) 33 (39%)
>10 6 (4%) 5 (6%) 1 (1%)
Not recorded 12 (7%) 8 (9%) 4 (5%)
Location of the tumor 0,66
Cervical 1 (1%) 1 (1%) 0
Upper third 7 (4%) 3 (3%) 4 (5%)
Middle third 76 (45%) 38 (45%) 38 (45%)
Distal third 71 (42%) 34 (40%) 37 (44%)
Not recorded 14 (8%) 9 (11%) 5 (6%)
Karnofsky score* 0,53
70 - 80 125 (74%) 60 (71%) 65 (77%)
90 - 100 38 (22%) 21 (24%) 17 (20%)
Not recorded 6 (4%) 4 (5%) 2 (3%)
Abbreviations: CS, Chemotherapy followed by surgery; S, Surgery alone
* Comparisons were made by the chi-square test
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the tumour. In this subgroup analysis, it appeared that
patients with substantial weight loss (>10%) treated with
preoperative chemotherapy had better overall survival as
compared to those who received surgery alone. Possibly,
patients allocated to chemotherapy and in a poor nutrition
status (eg weight loss >10%) were more likely to receive
nutritional support over a longer period of time as com-
pared to patients that were allocated to surgery alone.
This could have led to a better preoperative condition of
patients who received chemotherapy, which could possibly
contribute to improved overall survival. Furthermore,
patients with a tumour located in the middle thoracic
oesophagus who received preoperative chemotherapy had
better overall survival then patients who received surgery
alone. The explanation for the observed survival benefit in
this subgroup of patients is unclear.
Discussion
The long-term results of this randomized controlled
trial demonstrated a survival benefit for preoperative
chemotherapy followed by surgery in patients with
OSCC, when compared with surgery alone. This study
has only been reported in abstract form, which ham-
pers interpretation of our findings in context of other
randomized trials [9]. Why it took so long to report
the design and results of this study is not completely
understood. The main reasons are change of person-
nel (the trial coordinator [TCK] moved to another
hospital) and loss of interest in the used chemothera-
peutic regime. Nevertheless, we believe that these
results contribute to the ongoing debate about the
optimal (preoperative) therapy for patients with
OSCC.
Table 2 Surgical details
Total CS group S group
(N = 169) (N = 85) (N = 84) P-value
Surgery done 0,083
Yes 158 (93%) 76 (90%) 82 (98%)
No 9 (5%) 7 (8%) 2 (2%)
Not recorded 2 (2%) 2 (2%) 0
Reason no surgery undertaken
Died before surgery 3 (2%) 1 (1%) 2 (2%)
Progressive disease
Tumor unresectable 3 (2%) 3 (4%) 0
Distant metastases 3 (2%) 3 (4%) 0
Type of resection* 0,38
Transhiatal 113 (71%) 55 (72%) 58 (71%)
Transthoracic 20 (13%) 9 (12%) 11 (13%)
Type not recorded 5 (3%) 4 (5%) 1 (1%)
Other 1 (1%) 1 (1%) 0
No resection performed 19 (12%) 7 (10%) 12 (15%)
Postoperative deaths (within 30 days)* 7 (4%) 4 (5%) 3 (4%) 0,62
Non-fatal postoperative complications* 0,64
None 68 (43%) 30 (40%) 38 (46%)
Any 67 (42%) 33 (43%) 34 (41%)
Not recorded 16 (10%) 9 (12%) 7 (9%)
Type of non-fatal postoperative complications*,†
Pulmonary 25 (16%) 17 (23%) 8 (10%) 0,048
Cardiac 6 (4%) 3 (4%) 3 (4%) 1,0
Anastomotic
Subclinical 10 (6%) 5 (7%) 5 (6%) 1,0
Clinical 7 (4%) 3 (4%) 4 (5%) 1,0
Chylothorax 7 (4%) 4 (5%) 3 (4%) 0,70
Bleeding 5 (3%) 3 (4%) 2 (2%) 0,67
Vocal-cord injury 22 (14%) 10 (13%) 12 (15%) 0,82
Other 10 (6%) 4 (5%) 6 (7%) 0,75
Abbreviations: CS, Chemotherapy followed by surgery; S, Surgery alone
* Percentages based on total patients undergoing surgery.
† Nonfatal postoperative events; comparisons were made by the Fisher’s exact test
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The results of this study should be interpreted in the
timeframe in which this study was performed. This
study is one of the three largest randomized controlled
trials among patients with OSCC treated with preopera-
tive chemotherapy followed by surgery or surgery alone
[10,11]. All these large randomized controlled trials
were performed in the early ‘90s. The Medical Research
Council (MRC) trial included most patients with oeso-
phageal cancer (533 oesophageal adenocarcinoma
(OAC) and 247 OSCC patients) and demonstrated a
significant survival benefit for the use of preoperative
chemotherapy (P = .004) [11,12]. An other large and
well-conducted randomized controlled trial among
patients with oesophageal cancer (236 OAC and 204
OSCC patients), by the North American Intergroup
(RTOG Trial 8911 or USA Intergroup 113 trial; further
called the Intergroup trial), demonstrated no significant
difference in survival between patients treated with pre-
operative chemotherapy and those who received surgery
alone [10,13]. In the light of the results of both trials,
we discuss the design and results of the present study.
As most randomized controlled trials performed in the
early ‘90, this study reflects the methods for diagnosis,
staging, treatment delivery and outcome measurement
that indicate clinical practice during that period. In the
present study, the majority of patients (88%) underwent
preoperative staging by oesophago-gastroscopy and CT
scan of the chest and upper abdomen. The same preo-
perative staging methods were used in the Intergroup
trial. In the MRC trial, however, there was no standardi-
zation of preoperative staging. These differences in preo-
perative staging could, by selection of different
populations of OSCC patients, contribute to differences
in results between the trials.
In the Intergroup trial as well as in the MRC trial the
chemotherapeutic regime consists of cisplatin combined
with fluorouracil; in the present study cisplatin was
combined with etoposide. The ratio for this combination
Figure 2 Overall and disease free survival. A) Overall survival of all allocated patients. The distribution curves represent the results of an
intention-to-treat survival analysis involving all patients. Patients who received preoperative chemotherapy had a median survival of 16 months;
in comparison, patients who underwent only surgery had a median survival of 12 months (P = 0.03 by the log-rank test). B) Disease-free survival
of all patients from a landmark time of 6 months after date of randomisation (P = 0.02 by the log-rank test).
Table 3 Nature of first disease-free survival event
CS
group
S group
Event (N = 85) (N = 84) P-
value*
Disease free 12 (14%) 7 (8%) 0,33
No surgery performed 7 (8%) 2 (3%) 0,17
No resection performed 7 (8%) 12 (14%) 0,23
Macroscopic residual disease 3 (3%) 10 (12%) 0,05
2nd Primary 10 (12%) 4 (5%) 0,16
Local recurrence 16 (19%) 21 (25%) 0,36
Distant metastases 5 (6%) 5 (6%) 1
Local recurrence and distant metastases 9 (11%) 10 (12%) 0,81
Death with cancer but site of failure not
reported
5 (6%) 7 (8%) 0,57
Death from other or unspecified cause 11 (13%) 6 (7%) 0,31
* Comparisons were made by the Fisher’s exact test
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of chemotherapeutic agents was deducted from trials
among patients with non-small-cell lung cancer in
which this regime had showed to be safe and effective
[14]. Furthermore, a phase II trial in patients with
advanced OSCC had shown that the response rate
equals that of other cisplatin-based regimes and that the
toxicity profile was mild [8]. Patients without clinical
response to chemotherapy received a total preoperative
dose of 160 mg/m2 cisplatin and 1000 mg/m2 etoposide.
The dose of cisplatin is similar as compared with the
MRC trial (160 mg/m2). Patients with clinical response
to chemotherapy received total doses up to cisplatin 320
Figure 3 Survival by characteristics at randomisation and post-treatment. Centre of each square indicates hazard ratio, and area of square
the amount of information. Lines on either side indicate 95 CI.
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mg/m2 and etoposide 2000 mg/m2. In this subgroup of
patients, the total preoperative dose of cisplatin was
slightly higher as compared to the Intergroup trial (300
mg/m2). The compliance to chemotherapy was 88%
(patients who received two or more of the planned
cycles of chemotherapy). This is similar to 90% of the
patients that received both treatment cycles in the MRC
trial, but differed from the Intergroup wherein 71% of
the patients received all of three planned cycles of che-
motherapy. It has been suggested that the higher dose
of chemotherapy in the Intergroup trial was detrimental
to patients who underwent oesophagectomy. Other fac-
tors related to the chemotherapeutic regimes that could
contribute to the differences in outcome between the
three studies, are the use of chemoradiotherapy in a
subset of patients in the MRC trial and the use of post-
operative chemotherapy in a subgroup of patients in the
Intergroup trial.
In our study the majority of patients underwent a
transhiatal oesophagectomy. This type of resection is
associated with lower morbidity (and mortality) than a
transthoracic resection ([15]). In the other trials, the
type of surgical resection that has been performed is not
clear (MRC trial) or the exact numbers are not
described (Intergroup trial). The postoperative mortality
rate (<30 days after surgery) in the current trial was 5%
(4/76) in the CS group and 4% (3/82) in the S group
and differed not among both groups. These rates are
similar as those observed in the Intergroup trial, with
6% postoperative mortality in both treatment arms. In
contrast, the MRC trial reported much higher post-
operative mortality rate of 10% in the CS group and
11% in the S group.
In the present study surgery was performed in 89%
and 98% of patients in the CS group and S group,
respectively. Similar rates have been reported by the
MRC trial, with surgery rates in the CS group of 92%
and in the S group of 97%. In the Intergroup trial fewer
patients underwent surgery, 80% of the CS group and
92% of the S group. The rate of microscopically tumour
free resection margins (R0) in the CS group was 71%, as
compared to 60% and 62% in the CS groups of the
MRC and Intergroup trial, respectively. In the S group it
was 57%, as compared to 54% and 59% in the S groups
of the MRC and Intergroup trial, respectively. The dif-
ference in R0 resection rates between the CS group and
the S group is likely to contribute to the observed survi-
val benefit for patients treated with preoperative che-
motherapy (as showed by the MRC trial; P < 0.001),
however, this difference was not statistical significant in
the present study (P = 0.086).
The median survival time of the CS group was 16
months, compared to 17 and 15 months in the MRC
and Intergroup trial, respectively. The median survival
time of the S group was 12 months, compared to 16
and 13 months in the Intergroup and MRC trial, respec-
tively. It appears that the S group in our study had the
worst survival outcome, but this may be due to patient
selection. Both the MRC as Intergroup trial included
more OAC than OSCC patients. Subgroup analysis of
the MRC trial, including only OSCC patients, showed a
median survival time of 11 months for patients who
underwent surgery alone [12]. Remarkably, in the sub-
group analysis there is no significant survival benefit for
OSCC patients treated with preoperative chemotherapy
(P = 0.1).
In line with the results of the MRC and Intergroup
trial, there was no significant difference in pattern of
failure between both treatment arms in our study. The
rate of distant metastases was equal in both treatment
groups. These findings provide no evidence for the gen-
eral hypothesis that preoperative chemotherapy elimi-
nates systemic micro-metastases. The results of this trial
and the MRC trial suggest that the biologic effect of
preoperative chemotherapy seems to specifically influ-
ence the extent of surgery [12]. In the present study, the
incidence of incomplete resections was greater in the S
group, but sites of first recurrence (local or distant)
were similar. Furthermore, at 6 months, the DFS advan-
tage is established for the CS group (Figure 2A) and
remains consistent throughout follow-up as the survival
curves remain approximately parallel. This suggests that
the effect of preoperative chemotherapy is to reduce
tumour volume and increase the potential for curative
resection.
This study has its limitations. At first, the preoperative
staging was hampered by the absence of endoscopic
ultrasonography at the beginning of our trial. Therefore,
the clinical T- and N-stage were not used as stratifica-
tion parameters before randomization. Secondly, the
missing data on two patients that underwent preopera-
tive chemotherapy and the lack of some clinical charac-
teristics of the patients reflect the difficulty of obtaining
all data more than twenty years after the trial was per-
formed. At third, it should be noticed that we selected
patients who showed clinical response to chemotherapy
based on oesophago-gastroscopy and CT scan of the
chest and upper abdomen, for additional cycles of che-
motherapy. However, we did not correlate clinical
response to pathological response. Therefore, selection
of this subgroup could also reflect better prognostic
characteristics of patients who respond to chemother-
apy, rather than an effect of chemotherapy itself.
Conclusions
In summary, this study reports a significant survival
benefit for OSCC patients treated with preoperative che-
motherapy. The chemotherapeutic regime used in this
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trial (etoposide and cisplatin) is not used anymore in
treatment of patients with OSCC. Today, in our institu-
tion (EMC) the majority of patients with OSCC (and
OAC) receive preoperative chemoradiotherapy (a combi-
nation of carboplatin and paclitaxel, and concurrent
radiotherapy).
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